SUMMARY

A citizen submitted a request for access to the Ministry of Health to know the express resolution issued by the General Directorate of Basic Portfolio of Services of the National Health and Pharmacy System that establishes the financing conditions and price within the scope of the National Health System of the treatment Yescarta (axicabtagén ciloleucel), developed by Gilead Sciences

The Administration did not respond to the request for access.

Filed claim, the Council of Transparency and Good Governance considered it as this type of public information helps "promote an informed public debate on the problems of the current system of R&D and medical innovation and its impact on access to medicines and on the sustainability of health systems, inside and outside our country". This goal "in the spirit of the LTAIBG to know how the public authorities make the decisions that affect citizens, especially on the issue of public health and its financing, of marked social interest".